Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development

Molecular Cancer Research

Volumn 12, Issue 4, 2014, Pages 595-606

  Fortschegger, Klaus ^a   Anderl, Stefanie ^a   Denk, Dagmar ^a   Strehl, Sabine ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; ONCOPROTEIN; PAX5 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CHIMERA; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; LEUKEMIA; LEUKEMOGENESIS; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; CELL NUCLEUS; CONFOCAL MICROSCOPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; HEK293 CELLS; HELA CELLS; HUMANS; LEUKEMIA; MICROSCOPY, CONFOCAL; ONCOGENE PROTEINS, FUSION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84920134856     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0337     Document Type: Article

References (51)

1. Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol 2011;111:179-206.
2. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8:463-70.
3. Revilla-i-Domingo R, Bilic I, Vilagos B, Tagoh H, Ebert A, Tamir IM, et al. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J 2012;31:3130-46.
4. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007;27:49-63.
5. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006;24: 269-81.
6. McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir I, et al. The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. EMBO J 2011;30:2388-404.
7. Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene MC, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 2009;23:1989-98.
8. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64.
9. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009;23:134-43.
10. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood 2007;109:3417-23.
11. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001;61:4666-70.
12. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood 2010; 115:3089-97.
13. Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M, et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A 2008;105:11921-6.
14. Lee ST, Ji Y, Kim HJ, Ki CS, Jung CW, Kim JW, et al. Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia. Leuk Res 2012;36:418-21.
15. Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol 2007;139:269-74.
16. Denk D, Nebral K, Bradtke J, Pass G, Moricke A, Attarbaschi A, et al. PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia. Leuk Res 2012;36:e178-81.
17. Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. Dominantnegative mechanism of leukemogenic PAX5 fusions. Oncogene 2012;31:966-77.
18. Qiu JJ, Chu H, Lu X, Jiang X, Dong S. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia. Oncogene 2011;30:967-77.
19. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 2011;30:1822-30.
20. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008;68:181-9.
21. Fazio G, Cazzaniga V, Palmi C, Galbiati M, Giordan M, Te Kronnie G, et al. PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia 2012;27:992-95.
22. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
23. Hu CD, Chinenov Y, Kerppola TK. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol Cell 2002;9:789-98.
24. Czerny T, Busslinger M. DNA-binding and transactivation properties of Pax-6: three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5). Mol Cell Biol 1995;15:2858-71.
25. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, et al. DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 2003;278:51673-84.
26. Jorgl A, Platzer B, Taschner S, Heinz LX, Hocher B, Reisner PM, et al. Human Langerhans-cell activation triggered in vitro by conditionally expressed MKK6 is counterregulated by the downstream effector RelB. Blood 2007;109:185-93.
27. Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J. Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. Mol Cell Biol 2003; 23:1946-60.
28. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;12:2662-72.
29. Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT, et al. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol 2010; 220:87-96.
30. Fortschegger K, de Graaf P, Outchkourov NS, van Schaik FM, Timmers HT, Shiekhattar R. PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol Cell Biol 2010;30:3286-98.
31. Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM, et al. Identification of Pax5 target genes in early B cell differentiation. J Immunol 2008;180:1719-28.
32. Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, Greven MC, et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 2012;22:1798-812.
33. He T, Hong SY, Huang L, Xue W, Yu Z, Kwon H, et al. Histone acetyltransferase p300 acetylates Pax5 and strongly enhances Pax5-mediated transcriptional activity. J Biol Chem 2011;286: 14137-45.
34. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996;16:4107-16.
35. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997;16:69-82.
36. Okamoto N, Nishimori Y, Nishimura T. Conserved role for the Dachshund protein with Drosophila Pax6 homolog eyeless in insulin expression. Proc Natl Acad Sci U S A 2012;109:2406-11.
37. Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev 1996;10:2198-211.
38. Wheat W, Fitzsimmons D, Lennox H, Krautkramer SR, Gentile LN, McIntosh LP, et al. The highly conserved b-hairpin of the paired DNAbinding domain is required for assembly of Pax-Ets ternary complexes. Mol Cell Biol 1999;19:2231-41.
39. Hanson CA, Wood LD, Hiebert SW. Cellular stress triggers TEL nuclear export via two genetically separable pathways. J Cell Biochem 2008;104:488-98.
40. Li X, Zhang R, Luo D, Park SJ, Wang Q, Kim Y, et al. Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation. J Biol Chem 2005; 280:15061-70.
41. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genomewide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010;29:2147-60.
42. Garvie CW, Hagman J, Wolberger C. Structural studies of Ets-1/Pax5 complex formation on DNA. Mol Cell 2001;8:1267-76.
43. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res 2012;36:945-61.
44. Lee JW, KimHS, Hwang J, Kim YH, Lim GY, Sohn WJ, et al. Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBPalpha and GATA-1 in myeloid leukemia with MLL-AF9. Biochem Biophys Res Commun 2012;426:299-305.
45. Lee JW, Kim HS, Kim S, Hwang J, Kim YH, Lim GY, et al. DACH1 regulates cell cycle progression of myeloid cells through the control of cyclin D, Cdk 4/6 and p21Cip1. Biochem Biophys Res Commun 2012;420:91-5.
46. Kalverda B, Pickersgill H, Shloma VV, Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010;140:360-71.
47. Capelson M, Liang Y, Schulte R, Mair W, Wagner U, Hetzer MW. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 2010;140:372-83.
48. Gao H, Lukin K, Ramirez J, Fields S, Lopez D, Hagman J. Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. Proc Natl Acad Sci U S A 2009;106:11258-63.
49. Sigvardsson M, Clark DR, Fitzsimmons D, Doyle M, Akerblad P, Breslin T, et al. Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter. Mol Cell Biol 2002;22:8539-51.
50. Ikeda K, Watanabe Y, Ohto H, Kawakami K. Molecular interaction and synergistic activation of a promoter by Six, Eya, and Dach proteins mediated through CREB binding protein. Mol Cell Biol 2002;22: 6759-66.
51. Dimitrova L, Seitz V, Hecht J, Lenze D, Hansen P, Szczepanowski M, et al. PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma. Leukemia 2014; 28:213-6.